Amarin Analysts Say Vascepa Patent Settlement Not A Stock Mover, With 'Little Readthrough For Pending Patent Appeal'
Generic Threat To Amarin's Vascepa Overrides Positive Sentiment On Coronavirus Announcement
Leerink: Improving Fundamentals Drive Teva Upgrade
Leerink Upgrades Mylan On Barrage Of Catalysts, Diversified Platforms